Aspirin vs. clopidogrel monotherapy beyond 1 month after complex percutaneous coronary intervention: a pre-specified subgroup analysis of the STOPDAPT-3 trial
Authors' conclusion
There was a significant interaction between complex PCI and the effect of aspirin monotherapy relative to clopidogrel monotherapy beyond 1 month and up to 1 year for cardiovascular events due to numerically lower risk of aspirin monotherapy in patients with complex PCI, while the effect of aspirin monotherapy relative to clopidogrel monotherapy was not different for bleeding regardless of complex PCI.
Study context
- Population
- Patients after percutaneous coronary intervention (PCI) in the STOPDAPT-3 trial, by complex PCI30-day landmark analysis, 1415 patients (24.3%) underwent complex PCI · complex PCI 1,415
- Participants
- 5,833 patients
- Comparison
- The effect of the aspirin group relative to the clopidogrel group, by complex PCI
- Primary endpoint
- Co-primary endpoints: cardiovascular events (a composite of cardiovascular death, myocardial infarction, definite stent thrombosis, or stroke) and major bleeding (Bleeding Academic Research Consortium 3 or 5)
- Follow-up
- 30-day landmark analysis
Methodological details30-day landmark analysis, randomly compared
- 30-day landmark analysis
- Randomly compared
Primary result
As reported in the abstract
Cardiovascular events, complex PCI
Cardiovascular events, non-complex PCI
Bleeding events, complex PCI
Bleeding events, non-complex PCI
Further findings
Net adverse clinical events · 30-day landmark analysis
Complex PCI
Non-complex PCI
- Net adverse clinical events: interaction P = 0.02
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →